)
Viridian Therapeutics (VRDN) investor relations material
Viridian Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.LUMVOA launch
First-quarter launch revenue was $24.7 million, with >100 patients on therapy as of Sept. 30; management said execution exceeded expectations.
Most patients had a proptosis response after one infusion; chronic TED patients showed complete diplopia resolution, and the planned course is five infusions vs. TEPEZZA’s eight.
Management expects a fast path to peak in a new-start market, but said the actual timeline remains to be seen; launch is still early.
Commercial access and execution
Formal policy coverage reached 30% of covered lives by the end of September; other patients can pursue access through medical exceptions.
Payers indicated parity pricing could support parity coverage; TEPEZZA reached 85% of covered lives in nearly five years, while management targets critical mass within 6–9 months of launch.
More than 95% of ~2,000 core prescribers had been engaged within four weeks of launch; the field team was active with physicians within 24 hours of launch.
A permanent J-code takes effect Jan. 1; management expects limited overall impact, with potential help for smaller infusion centers.
SubQ elegrobart
After two positive Phase III readouts earlier in 2026, the BLA for subQ IGF-1R is planned for Q1 2027.
Development plans include Q4-weekly and Q8-weekly regimens; the Q8-weekly course would involve three administrations at day 1, week 8 and week 16.
Management expects subQ convenience to expand the market, particularly by reaching patients deterred by infusions; IV is expected to remain an option for controlled settings and severe, sight-threatening disease.
Q4-weekly data showed diplopia response and resolution; Q8-weekly dosing may suit patients whose primary concerns are proptosis or pain.
- Lumvoa launch gains traction as TED and autoimmune pipeline milestones advance.VRDN
Corporate presentation - Phase I data support Q8W VRDN-008, with MG registrational development planned for mid-2027.VRDN
Study update - Lumvoa generated $24.7M in its first quarter as elegrobart advanced toward a Q1 2027 BLA.VRDN
Q3 2026 - Strong Lumvoa IV launch and pipeline progress position for TED market expansion and leadership.VRDN
Wells Fargo 21st Annual Healthcare Conference - FDA approval and strong cash reserves drive commercial and pipeline momentum in TED.VRDN
Q2 2026 - Advancing toward BLA filing with strong phase 3 data, breakthrough status, and launch readiness.VRDN
Goldman Sachs 46th Annual Global Healthcare Conference - Lumvoa and elegrobart drive innovation in TED, with a robust pipeline for autoimmune expansion.VRDN
Company presentation - FDA approves Lumvoa for all forms of TED, offering rapid, durable relief and immediate access.VRDN
FDA announcement - Significant efficacy and safety in chronic TED support a 2027 BLA for a subcutaneous autoinjector.VRDN
Study result
Next Viridian Therapeutics earnings date
Next Viridian Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)